NCT02523014 2026-03-04
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
Clinical Trials
13 trialsNCT07294677 2026-03-04
CAVALRY
University of Chicago
Phase 1/2 Recruiting
NCT07281833 2026-02-27
CAPIcorn
West German Study Group
Phase 3 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06613516 2025-12-24
CaptAin
Imperial College London
Phase 2 Withdrawn
NCT05039801 2025-10-14
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06607757 2025-04-02
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
GBG Forschungs GmbH
Phase 2 Recruiting